Biomarker Type: Proteomic
-
Use of Two Blood-Based Biomarker Tests in Series to Reclassify Risk of Indeterminate Pulmonary Nodules
-
Lung Nodule Integrated Classifier Biomarker: First Data with Real-World Clinical Use
-
Identification of Likely Malignant Indeterminate Pulmonary Nodules by Analysis of Autoantibodies Against Lung Cancer Associated Antigens
-
Real World Data: Importance of Monitoring Blood Based KRAS Mutations and Immune Status in Patients with advanced NSCLC
-
A proposal for score assignment to characterize biological processes from mass spectral analysis of serum
-
Mass spectrometry-based serum proteomic signature as a potential biomarker for survival in patients with non-small cell lung cancer receiving immunotherapy
-
Prognostic performance of proteomic testing in advanced non-small cell lung cancer: a systematic literature review and meta-analysis
-
A Serum Protein Classifier Identifying Patients with Advanced Non-Small Cell Lung Cancer Who Derive Clinical Benefit from Treatment with Immune Checkpoint Inhibitors
-
Serum proteomic score for understanding response and mechanism of resistance to immune checkpoint inhibitors in non-small cell lung cancer
-
Serum proteomic score for understanding response and mechanism of immune-related adverse events (irAE) in non-small cell lung cancer